RNA-Dependent RNA Polymerase as a Target for COVID-19 Drug Discovery.
SLAS Discov
; 25(10): 1141-1151, 2020 12.
Article
in English
| MEDLINE | ID: covidwho-654127
ABSTRACT
COVID-19 respiratory disease caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has rapidly become a global health issue since it emerged in December 2019. While great global efforts are underway to develop vaccines and to discover or repurpose therapeutic agents for this disease, as of this writing only the nucleoside drug remdesivir has been approved under Emergency Use Authorization to treat COVID-19. The RNA-dependent RNA polymerase (RdRP), a viral enzyme for viral RNA replication in host cells, is one of the most intriguing and promising drug targets for SARS-CoV-2 drug development. Because RdRP is a viral enzyme with no host cell homologs, selective SARS-CoV-2 RdRP inhibitors can be developed that have improved potency and fewer off-target effects against human host proteins and thus are safer and more effective therapeutics for treating COVID-19. This review focuses on biochemical enzyme and cell-based assays for RdRPs that could be used in high-throughput screening to discover new and repurposed drugs against SARS-CoV-2.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Antiviral Agents
/
Viral Proteins
/
RNA-Dependent RNA Polymerase
/
Enzyme Inhibitors
/
COVID-19 Drug Treatment
Topics:
Vaccines
Limits:
Humans
Language:
English
Journal:
SLAS Discov
Year:
2020
Document Type:
Article
Affiliation country:
2472555220942123
Similar
MEDLINE
...
LILACS
LIS